Notice

You are leaving the HistoSonics Portal, which includes materials that discuss the benefits and risk of histotripsy and the indications for use statement for the Edison® System. You are being re-directed to educational and publicly available information from a third party. That information has not been reviewed by the Food & Drug Administration. HistoSonics is not responsible for third-party information and does not intend to promote any off-label use of the Edison® System or any clinical uses/benefits that have not been evaluated in an appropriately controlled clinical study.

Skip to content
  • Procedure Training & Guides
    • Edison System Reference Guides
    • Training Pathway
    • Clinical Workflow References
    • Evidence
  • Reimbursement
    • Hospital
    • Physician
  • IT Integration
    • IT Overview
    • IT Connections
    • Security Documents
  • Program Marketing
    • Brochures & Media Library
    • Community & Internal Education
    • Patient Education
    • Referring Physician Education
    • Site Set Up
  • Procedure Training & Guides
    • Edison System Reference Guides
    • Training Pathway
    • Clinical Workflow References
    • Evidence
  • Reimbursement
    • Hospital
    • Physician
  • IT Integration
    • IT Overview
    • IT Connections
    • Security Documents
  • Program Marketing
    • Brochures & Media Library
    • Community & Internal Education
    • Patient Education
    • Referring Physician Education
    • Site Set Up
linkedin
x
facebook

Welcome

Reset Password Register New User Account
logo
  • Procedure Training & Guides
  • Reimbursement
  • IT Integration
  • Program Marketing
Other Important Links
Histosonics Site Patient Site
linkedin
x
facebook

© 2026 HistoSonics All Rights Reserved.

Last updated on July 26, 2024

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

The Edison® System is intended for the non-invasive mechanical destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors via histotripsy. The FDA has not evaluated the Edison System for the treatment of any disease including, but not limited to, cancer or evaluated any specific cancer outcomes (such as local tumor progression, 5-year survival or overall survival). The System should only be used by persons who have completed training performed by HistoSonics, and its use guided by the clinical judgment of an appropriately trained physician. Refer to the device Instructions for Use for a complete list of warnings, precautions and a summary of clinical trial results, including reported adverse events.

Footer Last Updated June 17, 2024

Privacy Policy | Terms of Use | Site Powered by Brandography

Login Register